Physician profile
Ellen L Kehoe
NPI 1619975513
$2,972.81
in general payments reported to CMS, 2019-2025
21 companies · $228 in 2025
The $228 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $220 · 2021: $616 · 2022: $726 · 2023: $597 · 2024: $431 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $963.86 | 2019-2025 | Leqvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.82 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $307.02 | 2021-2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $298.22 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $175.03 | 2022-2025 | |
| Amgen INC. | $167.13 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $131.31 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $98.24 | 2024 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $97.72 | 2019-2024 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $69.81 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $52.00 | 2023 | |
| Lundbeck LLC | $44.38 | 2020-2021 | |
| Esperion Therapeutics, INC. | $36.91 | 2023-2024 | Nexletol |
| Amarin Pharma, INC. | $31.60 | 2020-2021 | |
| Medtronic, INC. | $28.92 | 2024 | Cobalt Dr Mri Surescan |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $28.51 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.15 | 2023 | |
| Irhythm Technologies, INC. | $15.28 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $14.42 | 2024 | |
| Bardy Diagnostics, INC. | $12.89 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Kehoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.